1. Home
  2. ALT vs BZAI Comparison

ALT vs BZAI Comparison

Compare ALT & BZAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • BZAI
  • Stock Information
  • Founded
  • ALT 1997
  • BZAI 2010
  • Country
  • ALT United States
  • BZAI United States
  • Employees
  • ALT N/A
  • BZAI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • BZAI
  • Sector
  • ALT Health Care
  • BZAI
  • Exchange
  • ALT Nasdaq
  • BZAI Nasdaq
  • Market Cap
  • ALT 348.6M
  • BZAI 343.8M
  • IPO Year
  • ALT N/A
  • BZAI N/A
  • Fundamental
  • Price
  • ALT $4.00
  • BZAI $4.03
  • Analyst Decision
  • ALT Strong Buy
  • BZAI Strong Buy
  • Analyst Count
  • ALT 7
  • BZAI 3
  • Target Price
  • ALT $16.50
  • BZAI $8.33
  • AVG Volume (30 Days)
  • ALT 2.7M
  • BZAI 4.1M
  • Earning Date
  • ALT 11-07-2025
  • BZAI 11-13-2025
  • Dividend Yield
  • ALT N/A
  • BZAI N/A
  • EPS Growth
  • ALT N/A
  • BZAI N/A
  • EPS
  • ALT N/A
  • BZAI N/A
  • Revenue
  • ALT $20,000.00
  • BZAI $3,771,000.00
  • Revenue This Year
  • ALT N/A
  • BZAI $2,295.50
  • Revenue Next Year
  • ALT N/A
  • BZAI $269.04
  • P/E Ratio
  • ALT N/A
  • BZAI N/A
  • Revenue Growth
  • ALT N/A
  • BZAI 114.63
  • 52 Week Low
  • ALT $2.90
  • BZAI $1.70
  • 52 Week High
  • ALT $11.16
  • BZAI $29.61
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.72
  • BZAI 45.09
  • Support Level
  • ALT $3.83
  • BZAI $4.11
  • Resistance Level
  • ALT $4.15
  • BZAI $4.81
  • Average True Range (ATR)
  • ALT 0.17
  • BZAI 0.60
  • MACD
  • ALT 0.00
  • BZAI -0.15
  • Stochastic Oscillator
  • ALT 58.90
  • BZAI 2.85

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About BZAI Blaize Holdings Inc. Common Stock

Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.

Share on Social Networks: